Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide.
Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory. In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.
Department of Urology, Kurume University School of Medicine, Asahimach 67, Kurume, Fukuoka, Japan. uemura_keiichirou@kurume-u.ac.jp
Keiichiro
K
Uemura
Kiyoaki
K
Nishihara
Tokumasa
T
Hayashi
Katsuro
K
Tomiyasu
Kei
K
Matsuoka
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016055:Urinary Retention / Q000188:drug therapy*
D002945:Cisplatin; D007069:Ifosfamide